Body mass index and age correlate with antioxidant supplementation effects on sperm quality: Post hoc analyses from a double-blind placebo-controlled trial by Busetto, Gian Maria et al.
Andrologia. 2020;00:e13523.	 	 	 | 	1 of 11
https://doi.org/10.1111/and.13523
wileyonlinelibrary.com/journal/and
1  | INTRODUC TION
The decline of male fertility is an emerging problem that has been 
widely reported. A recent meta-analysis analysing sperm counts 
in men seeking care for fertility problems in developed coun-
tries during the period from 1973 to 2011 showed that sperm 
counts have decreased by 50%–60% (Levine et al., 2017). Causes 
for these changes are lifestyle factors and global changes in our 
eating habits with increasing evidence of obesity, which is asso-
ciated with infertility and several medical conditions (Porreca et 
al., 2018; Rufus, James, & Michael, 2018). While an association 
between obesity and female infertility has been clearly proven 
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Abstract
Spermatozoa are vulnerable to lack of energy and oxidative stress as a result of el-
evated levels of reactive oxygen species. Therefore, it is essential that appropriate 
nutrients are available during maturation. This randomised, double-blind, placebo-
controlled trial investigated the effect of 6-month supplementation with carnitines 
and	 other	micronutrients	 on	 sperm	quality	 in	 104	 subjects	with	 oligo-	 and/or	 as-
theno- and/or teratozoospermia with or without varicocele. Semen analyses were 
done at the beginning and end of the treatment. In addition to main analyses, post 
hoc analyses for age and body mass index (BMI) were carried out. Results were inter-
preted	by	dividing	the	population	into	two	age	and	BMI	classes.	In	94	patients	who	
completed the study, all sperm parameters increased in supplemented patients com-
pared to the placebo group. A significant (p = .0272) difference in supplementation 
efficacy was observed for total motility on patients with varicocele and BMI < 25. In 
the same group, also the progressive motility was significantly superior (p = .0159). 
For Responder analysis, total motility results were confirmed in both the cited group 
(p = .0066) and in the varicocele group with BMI < 25 and age < 35 (p = .0078). This 
study suggests that supplementation is more effective in subjects with varicocele 
younger than 35 years with BMI < 25.
K E Y W O R D S
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2 of 11  |     BUSETTO ET al.
(Pinborg et al., 2011), a definitive association with male infertil-
ity is still lacking. Nevertheless, a relationship can be postulated 
when examining the decline in male fertility and the concomitant 
increase in obesity (Verón et al., 2018). The potential relationship 
between male infertility and obesity could be due to a decrease 
in androgen secretion resulting in poorer semen quality and a 
deterioration in mitochondrial activity (Rufus et al., 2018). Male 
age could be another factor negatively influencing male fertility. 
In general, men maintain a certain lifelong fertility, but hormonal 
status, sexual function and sperm production can decline with ad-
vanced	paternal	age	(Belloc	et	al.,	2014).	Significant	decreases	in	
semen volume, motility, morphology and sperm count have also 
been reported in men with advanced age (Hellstrom et al., 2006; 
Kidd, Eskenazi, & Wyrobek, 2001). Moreover, sperm chromatin 
and DNA integrity have been shown to be negatively impacted 
with ageing and obesity (Das et al., 2013; Thomsen, Humaidan, 
Bungum,	&	Bungum,	2014).
As another major cause of male infertility, oxidative stress (OS) 
may affect the male germ cells, causing sperm DNA damage and 
dysfunction. As male germ cells have an extraordinary high content 
of polyunsaturated fatty acids in plasma membranes, spermato-
zoa are highly vulnerable to reactive oxygen species (ROS), which 
in turn leads to membrane damage through lipid peroxidation, and 
finally, cell death is caused by functional alterations (Agarwal et al., 
2014).	OS	occurs	when	there	is	an	imbalance	between	oxidants	and	
antioxidants in favour of the oxidants. For normal sperm function, 
including chromatin compaction in maturing spermatozoa during ep-
ididymal transit, a delicate balance of reduction and oxidation is re-
quired (Agarwal, Hamada, & Esteves, 2012; Wright, Milne, & Leeson, 
2014).	Elevated	ROS	levels	without	adequate	compensation	damage	
fertility, but a small quantity of ROS is required to trigger essential 
physiological reactions for normal sperm maturation and function 
(Agarwal	et	al.,	2014).	Ageing	 is	also	related	to	an	 increase	 in	 lipid	
peroxidation, oxidation of proteins and DNA (Harman, 1992). Since 
obesity is associated with a general systemic inflammatory status, 
this also results in OS. More specifically, leptin, interleukin cascades, 
TNF-α accumulation and other mechanisms are able to produce 
large amounts of peroxynitrite and other oxidants (Abdali, Samson, 
& Grover, 2015).
Antioxidants including vitamins, metabolic coenzymes, carni-
tines (L-carnitine and acetyl-L-carnitine) and micronutrients (zinc, 
selenium, folic acid) are required for sperm formation and matu-
ration and, due to poor diet, are often deficient, resulting in a de-
crease in the antioxidant status as well as mitochondrial dysfunction 
(Busetto et al., 2018; WHO, 2011). Several studies demonstrate 
that antioxidant supplementation could positively act on fertility by 
improving sperm quality and is therefore recommended as poten-
tially effective therapy for the treatment of male infertility. With 
ageing and obesity as causes of OS, a therapeutic strategy could be 
to use these supplements to minimise free radical damage, increase 
sperm energy metabolism and thereby improve cellular processes 
connected with the formation and maturation of spermatozoa. In 
particular, it is known that antioxidants are able to protect sper-
matozoa from ROS damages, decrease DNA fragmentation, reduce 
cryodamage to spermatozoa and block premature sperm maturation 
(Busetto et al., 2018).
If ageing is increasingly connected with failure to achieve father-
hood and obesity showing growing evidence of being negatively 
associated with male fertility, these variables should correlate with 
male infertility. At present, no studies investigated the correlation 
of age and body mass index (BMI) with the efficiency of a medical 
therapy in infertile men. Therefore, the objective of this randomised, 
double-blind, placebo-controlled trial was to evaluate the effect of 
antioxidant supplementation with selected natural compounds on 
sperm quality. The effects were evaluated in subjects with oligo- 
and/or astheno- and/or teratozoospermia and were subsequently 
analysed across different age and BMI classes.
2  | MATERIAL S AND METHODS
2.1 | Patients and study design
The present analysis stems from the extensive database that has 
been created to determine the effects of antioxidant supplementa-
tion	on	semen	quality.	This	database	includes	104	infertile	patients	
with oligo- and/or astheno- and/or teratozoospermia with an av-
erage	 age	 of	 32.5	 years	 (range	 18–48),	 enrolled	 in	 a	 randomised,	
double-blind,	placebo-controlled	trial	between	December	2014	and	
June 2015. All participants were enrolled at the Andrology clinic at 
the Department of Gynecological-Obstetric Sciences and Urological 
Sciences, ‘‘Sapienza’’ Rome University. Included are 52 patients 
with grade I–III varicoceles and 52 patients without varicocele that 
were divided into supplementation or placebo groups (Busetto et al., 
2018).
The Ethics Committee of the Department of Gynecological-
Obstetric Sciences and Urological Sciences, ‘‘Sapienza’’ Rome 
University, approved the study protocol (Institute Ethical Approval 
Number PXP-001A). The study was conducted in line with European 
Urology and Good Clinical Practice guidelines, with ethical princi-
ples laid down in the latest version of the Declaration of Helsinki. 
Informed consent was documented for every patient who partici-
pated in the study.
The study was registered on clinicaltrial.gov, and the assigned 
number	is	NCT04177667.
2.2 | Randomisation and blindness
The randomisation list was prepared with the nQuery Advisor nTerim 
2.0 (2012) program. Two separate lists, one for each varicocele stra-
tum, were prepared. Subjects were randomly assigned to one of the 
two regimens receiving either the supplementary active product or 
the placebo product.
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This is a double-blind study, and neither the patient nor investi-
gators, responsible for collecting data or analysing laboratory spec-
imens, were knowledgeable regarding the assignment of active or 
placebo product. A file was maintained at each of the sites under 
the responsibility of the primary investigator which provided the 
product identification for each subject. Once the subject entered 
into the study, they were assigned a unique study identification 
number.
2.3 | Inclusion and exclusion criteria
In our trial, we have included men aged between 18 and 50 years, 
with oligo- and/or astheno- and/or teratozoospermia, with or with-
out varicocele (not surgically treated) and men from couples with 
history of difficulty conceiving for more than 12 months. Patients 
without varicocele were affected by idiopathic male infertility. A 
complete check-up to exclude any other cause of infertility (history, 
examination, complete ultrasound and Doppler, hormones and ge-
netic tests) was done to all participating subjects. Even female part-
ners have been studied, and it was required: regular menstrual cycle, 
age	<	40	and	couples	not	undergoing	any	assisted	reproductive	tech-
nology (ART).
Exclusion criteria were as follows: known hypersensitivity to 
any of the compound, history of undescended testes or cancer, en-
docrine disorders, history of post-pubertal mumps, genitourinary 
surgery, obstructive azoospermia or obstructive pathology of the 
urogenital system, autoimmune disease, cystic fibrosis, history of 
taking any therapy affecting fertility, excessive consumption of al-
cohol or regular use of illicit or ‘recreational’ drugs, positive serology 
for HIV, subjects following any special diet or taking antioxidants, 
any systemic condition which in the opinion of the investigator might 
put the subject at risk by participation in this study and subjects in-
volved in any other clinical trials.
Group Class Statistics Placebo Supplementation p-value
With varicocele Age < 35 N 13 18 .6365
Mean 5.27 9.02
Std. Dev. 21.03 21.92
Without varicocele Age < 35 N 18 16 .2372
Mean 6.79 14.76
Std. Dev. 20.76 17.37
With varicocele Age	≥	35 N 13 8 .1296
Mean −4.98 8.43
Std. Dev. 21.22 13.79
Without varicocele Age	≥	35 N 8 10 .6744
Mean −5.66 −2.55
Std. Dev. 14.56 15.91
With varicocele BMI < 25 N 19 20 .1173
Mean 0.89 11.57
Std. Dev. 20.06 21.46
Without varicocele BMI < 25 N 22 21 .7702
Mean 4.16 5.9
Std. Dev. 20.32 18.46
With varicocele BMI	≥	25 N 7 6 .8867
Mean −1.87 −0.28
Std. Dev. 26.18 4.48
Without varicocele BMI	≥	25 N 4 5 .1138
Mean −3.63 17.34
Std. Dev. 16.22 18.07
With varicocele Age < 35 & 
BMI < 25
N 10 13 .3749
Mean 4.95 13.15
Std. Dev. 16.28 24.72
Without varicocele Age < 35 & 
BMI < 25
N 15 13 .4256
Mean 7.32 13.48
Std. Dev. 22.74 16.45
TA B L E  1   Sperm concentration (106 ml)
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2.4 | Treatment
In accordance with the randomisation schedule, subjects received 
2 packets of either supplement (1,000 mg of L-carnitine, 725 mg of 
fumarate, 500 mg of acetyl-L-carnitine, 1,000 mg of fructose, 50 mg 
of citric acid, 50 µg of selenium, 20 mg of coenzyme Q10, 90 mg 
of vitamin C, 10 mg of zinc, 200 µg of folic acid and 1.5 µg of vi-
tamin B12—Alfasigma Health Science, Utrecht, The Netherlands) or 
placebo daily for 6 months. Semen parameters were evaluated in a 
standard semen analysis at the beginning of the treatment (V1) and 
after completing 6 months of therapy (V2). Variables taken into con-
sideration were ejaculate volume (ml), total sperm count (106), pro-
gressive motility (%), total motility (%) and normal sperm morphology 
(%). Pregnancy rate was included as a secondary outcome. An in-
ternal quality control, including intra-operator and/or inter-operator 
controls, was performed. An external quality control, as well, was 
included, in order to provide a blind evaluation of semen samples 
regarding concentration, motility and morphology.
2.5 | Statistical Analyses
Analysis of covariance was performed with 2 groups (verum 
or placebo, with and without varicocele) and was defined as 
f = σm/σ = 0.25 with the correlation coefficient (R2) between 
the baseline and final equal to 0.50. It was also designated that 
α = 0.05 (significance) and β = 0.20 (power of 80%). Up to 15% 
of	 patients	 dropping	 out	 of	 the	 study	were	 estimated,	 and	 104	
patients (52 per arm) were enrolled.
All continuous variables are reported as mean, median, stan-
dard deviations, and minimum and maximum values. Discrete 
and nominal variables are reported as frequency and percentage 
in contingency tables. The basal homogeneity of the groups was 
tested using analysis of variance (ANOVA) with two levels (drug 
and varicocele). The independent variable was the value detected 
at the baseline visit, while the dependent variable was the value 
detected at the end of treatment. The Wilcoxon rank-sum test 
was adopted for comparing the two groups at baseline while the 
Group Class Statistics Placebo Supplementation p-value
With varicocele Age < 35 N 13 18 .2134
Mean −0.35 0.28
Std. Dev. 1.03 1.58
Without varicocele Age < 35 N 18 16 .4411
Mean −0.14 −0.5
Std. Dev. 1.42 1.21
With varicocele Age	≥	35 N 13 8 .5568
Mean −0.26 0.09
Std. Dev. 1.22 1.33
Without varicocele Age	≥	35 N 8 10 .6719
Mean 0.66 0.46
Std. Dev. 0.89 1.06
With varicocele BMI < 25 N 19 20 .3345
Mean −0.25 0.16
Std. Dev. 1.22 1.4
Without varicocele BMI < 25 N 22 21 .929
Mean 0.13 0.17
Std. Dev. 1.41 1.12
With varicocele BMI	≥	25 N 7 6 .2864
Mean −0.46 0.43
Std. Dev. 0.95 1.85
Without varicocele BMI	≥	25 N 4 5 .0514
Mean −0.05 −1.38
Std. Dev. 0.79 0.89
With varicocele Age < 35 & 
BMI < 25
N 10 13 .3141
Mean −0.54 0.05
Std. Dev. 1.09 1.55
Without varicocele Age < 35 & 
BMI < 25
N 15 13 .864
Mean −0.13 −0.22
Std. Dev. 1.54 1.1
TA B L E  2   Volume of ejaculate (ml)
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Wilcoxon signed-rank test was used in the comparisons before/
after by group.
In addition to the main analyses, as designed in the study proto-
col, the present post hoc analyses were carried out on the samples as 
categorised by age/BMI and presence/absence of varicocele. Eight 
subgroups were considered (two age classes and two weight classes 
and presence/absence of varicocele): age less (1) than or greater (2) 
than 35 years old and BMI less (a) than or greater (b) than 25. The lat-
ter cut-off was suggested by the clinicians since that level is usually 
considered as the upper limit of the range for the normal BMI class 
while the age cut-off, that is 35 years, was adopted as in our opinion 
is considered, in western countries, as the common age for seek-
ing paternity. Age was calculated in years, and BMI was calculated 
by the standard method of kg/m2. All the main semen parameters 
were analysed as difference at the final visit from the baseline (val-
ues before the trial). The t test was adopted for detecting possible 
differences between the two treatment groups. BMI and age were 
also analysed in combination, to obtain another evaluation and to 
see whether the two factors further changed therapy effect. Once 
the classes in which the supplementary product seemed to be more 
effective were identified, the final analysis was performed conduct-
ing the same test. In order to confirm the results, the data were 
arranged as a before/after dataset and the patients were catego-
rised as Responder/Nonresponder (i.e. a patient was considered as 
‘Responder’ if he improved the results at final visit from baseline). 
The chi-square test was carried out on those data. SAS® version 
9.4	(Cary,	NC,	USA)	was	used	for	performing	all	statistical	analyses.
3  | RESULTS
Out	of	104	enrolled	patients,	94	completed	the	study	(90.4%),	with	
the homogeneity tests showing two well-balanced groups. Adverse 
events occurred only in the supplement group, and all events were 
not serious, with four patients experiencing nausea and three having 
vertigo or headache.
Group Class Statistics Placebo Supplementation p-value
With varicocele Age < 35 N 13 18 .149
Mean 12.1 50.27
Std. Dev. 72.77 69.26
Without varicocele Age < 35 N 18 16 .316
Mean 28.9 41.6
Std. Dev. 31.54 41.02
With varicocele Age	≥	35 N 13 8 .1219
Mean −12.13 42.78
Std. Dev. 59.59 96.79
Without varicocele Age	≥	35 N 8 10 0.812
Mean 14.86 19.55
Std. Dev. 37.44 43.29
With varicocele BMI < 25 N 19 20 .0272
Mean 0.4 55.63
Std. Dev. 65.34 83.1
Without varicocele BMI < 25 N 22 21 .6528
Mean 30.6 35.71
Std. Dev. 30.34 42.81
With varicocele BMI	≥	25 N 7 6 .5185
Mean −1.15 22.39
Std. Dev. 74.28 47.17
Without varicocele BMI	≥	25 N 4 5 .2853
Mean −8.55 22.22
Std. Dev. 33.19 43.88
With varicocele Age < 35 & 
BMI < 25
N 10 13 .0789
Mean 1.88 58.25
Std. Dev. 68 75.81
Without varicocele Age < 35 & 
BMI < 25
N 15 13 .4737
Mean 33.87 43.49
Std. Dev. 30.79 39.14
TA B L E  3   Total sperm count (106)
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3.1 | Semen volume
Overall, results showed no difference in semen volume, before and 
after the treatment, both in the placebo group (p = .6787) and the 
supplemented group (p = .6271). Including only varicocele patients, 
before and after treatment, no difference was observed in both the 
placebo and supplemented group, p = .2250 and p = .3632 respec-
tively. Patients without varicocele showed no statistically significant 
difference before/after in both the placebo group (p = .7711) and the 
supplemented group (p = .8753).
3.2 | Total sperm count
Comparing all patients of the placebo group, the treatment re-
sulted in no change for the total sperm count (p = .2030). In con-
trast, total sperm count in the supplemented group increased highly 
significantly (p < .0001). For patients suffering from varicocele, no 
difference was observed in the placebo group (p	=	 .8764),	while	a	
statistically significant (p = .0066) improvement in favour of the sup-
plemented group was obvious. For nonvaricocele subjects, in both 
the placebo and supplementation groups, no significant difference 
was observed (p	=	.4259	and	p	=	.2460).
3.3 | Progressive motility
For progressive motility, the treatment resulted in no difference 
(p = .1567) in the placebo group. In contrast, in the supplemented 
group a significant (p = .0012) increase in progressive motility was 
obvious at the final visit. In varicocele patients, no difference was 
seen with the placebo (p = .1570), whereas a significant difference 
was recorded in the supplemented group. In nonvaricocele patients, 
the results were again significant in the treated arm (p = .0311) and 
not significant in the placebo arm (p	=	.4866).
3.4 | Total motility
The overall results for total motility, before and after therapy, re-
vealed no difference in the placebo group (p	=	.1483),	but	a	significant	
difference (p < .0001) in the supplemented group. In the varicocele 
group, the results in the placebo group were once again statistically 
not significant (p	=	 .1214),	while	total	motility	 in	the	treated	group	
was significantly (p = .0065) higher. As for the group without varico-
cele, the results did not differ (p	=	.5604)	in	the	placebo	group	when	
comparing the initial results with those at the final visit. In contrast, in 
the treated group, total motility was significantly (p = .0028) higher.
3.5 | Sperm morphology
Results reported no difference in normal sperm morphology be-
tween the placebo group and the supplemented group, at baseline 
(p = .2062) and at the end of the study (p = .3791). On the other hand, 
whereas the placebo group had significantly lower values of normal 
sperm morphology at the final visit (p = .0105), results in the supple-
mented group did not differ (p = .1310).
Group Treatment Nonresponder Responder Total p-value
Age < 35
With 
varicocele
Supplementation 5 (27.8%) 13 (72.2%) 18 .0601
Placebo 8 (61.5%) 5 (38.5%) 13
Total 13 18 31
Age < 35
Without 
varicocele
Supplementation 2 (12.5%) 14	(87.5%) 16 .2715
Placebo 5 (27.8%) 13 (72.2%) 18
Total 7 27 34
BMI < 25
With 
varicocele
Supplementation 5 (25.0%) 15 (75.0%) 20 .0066
Placebo 13	(68.4%) 6 (31.6%) 19
Total 18 21 39
BMI < 25
Without 
varicocele
Supplementation 4	(19.0%) 17 (81.0%) 21 .7669
Placebo 5 (22.7%) 17 (77.3%) 22
Total 9 34 43
Age < 35 and 
BMI < 25
With 
varicocele
Supplementation 2	(15.4%) 11	(84.6%) 13 .0078
Placebo 7 (70.0%) 3 (30.0%) 10
Total 9 14 23
Age < 35 and 
BMI < 25
Without 
varicocele
Supplementation 1 (7.7%) 12 (92.3%) 13 .3533
Placebo 3 (20.0%) 12 (80.0%) 15
Total 4 24 28
TA B L E  4   Total sperm count (106)—chi-
square test
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3.6 | Pregnancy rate
As a secondary outcome, 12 pregnancies occurred during the 
6 months of follow-up time: 10 in the supplementation group and 2 
in the placebo group. The chi-squared test showed that the differ-
ence between the two groups was statistically significant (p	=	.0141).
3.7 | Body mass index and age correlation
One of the primary aims of this study was to correlate the results 
of the semen analysis with BMI and age. In particular, we wanted 
to see if ageing and obesity status would decrease efficacy of the 
supplementary antioxidant treatment on main sperm parameters 
(see	Tables	1‒7).	For	BMI,	a	significant	difference	was	observed	 in	
the BMI < 25 group with varicocele for total sperm count (p = .0272, 
see Table 3) and progressive motility (p = .0159, see Table 5). No 
statistical significance was observed in the combined classes. The 
results were partially confirmed by carrying out the chi-square test 
on the data arranged as ‘Responder/Nonresponder’ (see above). As 
for the total sperm count, in both the BMI < 25 and the combined 
varicocele group (i.e. BMI < 25 and age < 35) a statistical difference 
was observed (p = .0066 and p	=	 .0078,	respectively,	see	Table	4).	
These post hoc analyses suggest that the nutritional supplement 
seems to be more effective in subjects younger than 35 years with 
a BMI below 25.
4  | DISCUSSION
Ageing and obesity are two modern global problems. BMI is the com-
mon	parameter	used	to	measure	obesity,	and	a	value	≥	25	is	consid-
ered overweight (WHO, 2011). Obesity harms health and longevity; 
increased visceral fat tissue adds to the risk of age-related disease 
Group Class Statistics Placebo Supplementation p-value
With varicocele Age < 35 N 13 18 .5159
Mean 2.16 4.18
Std. Dev. 7.1 9.28
Without varicocele Age < 35 N 18 16 .3979
Mean 4.11 7.71
Std. Dev. 9.35 14.84
With varicocele Age	≥	35 N 13 8 .3628
Mean 1.58 4.1
Std. Dev. 6.28 5.54
Without varicocele Age	≥	35 N 8 10 .0831
Mean −5.15 3.52
Std. Dev. 11.14 8.79
With varicocele BMI < 25 N 19 20 .0159
Mean 0.87 5.93
Std. Dev. 4.48 7.55
Without varicocele BMI < 25 N 22 21 .1905
Mean 1.85 6.69
Std. Dev. 9.67 13.89
With varicocele BMI	≥	25 N 7 6 .2524
Mean 4.57 −1.75
Std. Dev. 10.4 8.06
Without varicocele BMI	≥	25 N 4 5 .5133
Mean −1.95 3.64
Std. Dev. 16.5 7.22
With varicocele Age < 35 & 
BMI < 25
N 10 13 .0599
Mean −0.12 6.12
Std. Dev. 4.5 9.07
Without varicocele Age < 35 & 
BMI < 25
N 15 13 .3311
Mean 4.12 8.94
Std. Dev. 8.88 16.28
TA B L E  5   Progressive motility (%)
8 of 11  |     BUSETTO ET al.
and early mortality, in part because of a systemic state of increased 
oxidative stress and inflammation (Tzanetakou, Katsilambros, 
Benetos, Mikhailidis, & Perrea, 2012). Ageing is connected with cel-
lular ageing and endocrinological and metabolic changes. A cells’ age 
is based on the number of times they have replicated. However, due 
to ageing, telomeres are shortened after many replications with the 
result that the genetic material is no longer able to be copied ac-
curately. Even hormone levels fluctuate through life and are thus 
able to drive cells’ behaviour. Exposure to toxins, sun, foods, pol-
lution and smoking leads to tissue damage as the body falls behind 
in its ability to maintain and repair cells, tissues and organs. Even 
metabolic processes and cellular energy production are negatively 
affected over time (Labat-Robert & Robert, 2015; Russell & Kahn, 
2007). Thus, ageing and obesity increase the onset of metabolic 
imbalances, leading to a reduced lifespan and accelerated cellular 
degradation processes such as deterioration of the structure and 
function of organs associated with genetic instability and distur-
bance of homeostatic pathways (Ahima, 2009). Male fertility, as an 
important biological process, may suffer as a result of increased BMI 
and age. Nevertheless, mechanisms that directly link obesity and 
ageing with lower fertility have not been confirmed.
Kasturi et al. linked obesity to metabolic syndrome (MetS), and 
the accompanying pro-inflammatory state may lead to inflammation 
and oxidative stress, which can in turn cause DNA alterations and 
testicular damage (Kasturi, Tannir, & Brannigan, 2008). Other authors 
confirmed this relationship by analysing sperm parameters and body 
weight. Even sperm DNA integrity worsens with increased body 
weight as the overweight status is directly associated with a higher 
DNA fragmentation index (DFI) (Dupont et al., 2013; Kort et al., 2006). 
Another important mechanism relating infertility with an increased 
BMI is found in hormonal changes related to obesity. Decreased sex 
hormone-binding globulin (SHBG) binding capacity, increased estro-
gens, decreased luteinising hormone (LH) and decreased testoster-
one are mainly caused by hyperinsulinemia and hyperlipidemia and 
are common in obese patients (Aggerholm, Thulstrup, Toft, Ramlau-
Hansen, & Bonde, 2008). All of these hormonal alterations can af-
fect sperm parameters by acting on mitochondrial function, DNA 
fragmentation, oxidative stress and increased likelihood of miscar-
riage (Engin-Ustun et al., 2018). On the other hand, some authors 
reported that an association between BMI and male fertility cannot 
be established and patients should be reassured that semen quality 
is not affected by obesity (Rufus et al., 2018). Even some meta-anal-
yses are contradictory, reporting in one case a statistically significant 
association between body weight and semen parameters, while in 
other studies no relation was found (MacDonald, Herbison, Showell, 
& Farquhar, 2010; Sermondade et al., 2013).
Paternal age is reported to be another important factor involved 
in fertility changes (Mazur & Lipshultz, 2018). As with the overweight 
status, hormones are altered and FSH and testosterone decreases 
are commonly observed in older men. Reportedly, an FSH decrease 
is the cause of reduced Sertoli cell function, germ cell degeneration 
and reduced daily sperm production (Johnson, Grumbles, Bagheri, 
& Petty, 1990). Moreover, sperm and seminal parameters are also 
affected by ageing with declining semen volume, sperm motility and 
morphology	(Belloc	et	al.,	2014;	Sloter	et	al.,	2006).	DNA	fragmen-
tation and sperm chromatin compaction are altered and associated 
with lower sperm quality and reduced pregnancy rate (Loft et al., 
2003). Several trials correlating age with DNA quality have shown 
Group Treatment Nonresponder Responder Total p-value
Age < 35
With 
varicocele
Supplementation 8	(44.4%) 10 (55.6%) 18 .3473
Placebo 8 (61.5%) 5 (38.5%) 13
Total 16 15 31
Age < 35
Without 
varicocele
Supplementation 4	(25.0%) 12 (75.0%) 16 .3876
Placebo 7 (38.9%) 11 (61.1%) 18
Total 11 23 34
BMI < 25
With 
varicocele
Supplementation 5 (25.0%) 15 (75.5%) 20 .0368
Placebo 11 (57.9%) 8	(42.11%) 19
Total 16 23 39
BMI < 25
Without 
varicocele
Supplementation 7 (33.3%) 14	(66.7%) 21 .2681
Placebo 11 (50.0%) 11 (50.0%) 22
Total 18 25 43
Age < 35 and 
BMI < 25
With 
varicocele
Supplementation 4	(30.8%) 9 (69.2%) 13 .0619
Placebo 7 (70.0%) 3 30.0%) 10
Total 11 12 23
Age < 35 and 
BMI < 25
Without 
varicocele
Supplementation 3 (23.1%) 10 (76.9%) 13 .3389
Placebo 6	(40.0%) 9 (60.0%) 15
Total 9 19 28
TA B L E  6   Progressive motility (%)—chi-
square test
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that DNA damage is commonly present in ageing men and this has 
been observed not only in infertile populations, but also even in 
healthy people (Belloc et al., 2009; Heidari et al., 2016). Isolated 
sperm DNA defects are also more prevalent in older men as com-
pared to younger men [8].
With regard to varicocele, there are numerous reports associat-
ing this condition with male infertility (Agarwal et al., 2012; Busetto 
et al., 2018; Heidari et al., 2016). This condition is characterised by 
elevated seminal ROS levels and oxidative stress leading to sperm 
dysfunction. Mitochondria, when damaged or dysfunctional, are a 
key source of ROS, and their gene alterations can affect the respi-
ratory electron transfer chain (Heidari et al., 2016). This process, 
maybe because of ATP synthesis alteration, ultimately interferes 
with sperm motility and fertility (Heidari et al., 2016). Latest re-
ports in the field of proteomics show that the proteomic profile 
of patients with varicoceles are significantly different (Panner & 
Agarwal, 2019).
Antioxidants are commonly used as medical therapy for male in-
fertility, and studies demonstrate that their use has a beneficial ef-
fect	on	fertility	(Wright	et	al.,	2014;	Busetto	et	al.,	2018).	Even	if	low	
levels of reactive oxygen species are required for sperm production, 
oxidative stress represents the main cause of DNA fragmentation 
and sperm dysfunction (Aitken, 1997). In fact, when OS is high and 
an uncontrolled release of ROS can be found, sperm motility is low, 
while membrane lipid peroxidation, protein oxidation and sperm DNA 
damage are elevated (de Lamirande, Jiang, Zini, Kodama, & Gagnon, 
1997). In such cases, antioxidants are recommended as potentially 
effective therapy for the treatment of male infertility as these com-
pounds scavenge excessive ROS. In turn, this can then result in in-
creased sperm quality and decreased DNA fragmentation through 
reduced oxidative stress (Micic et al., 2019). Supplementation of vital 
antioxidants in the reproductive tract in antioxidant-deficient pa-
tients could be a strategy to increase the ROS-scavenging capacity 
of seminal plasma and thereby reducing seminal OS. On the other 
Group Class Statistics Placebo Supplementation p-value
With varicocele Age < 35 N 13 18 .3438
Mean 1.89 5.06
Std. Dev. 7.65 9.91
Without varicocele Age < 35 N 18 16 .0711
Mean −0.5 7.53
Std. Dev. 12.21 12.84
With varicocele Age	≥	35 N 13 8 .8897
Mean 3.93 4.53
Std. Dev. 10.26 7.72
Without varicocele Age	≥	35 N 8 10 .2955
Mean 1.38 8.14
Std. Dev. 13.87 12.63
With varicocele BMI < 25 N 19 20 .1766
Mean 1.81 5.73
Std. Dev. 8.27 9.44
Without varicocele BMI < 25 N 22 21 .1127
Mean 2.45 8.4
Std. Dev. 10.25 13.64
With varicocele BMI	≥	25 N 7 6 .4911
Mean 5.91 2.12
Std. Dev. 10.61 8.18
Without varicocele BMI	≥	25 N 4 5 .0624
Mean −12.98 5.1
Std. Dev. 17.22 6.05
With varicocele Age < 35 & 
BMI < 25
N 10 13 .0904
Mean 0.28 7.01
Std. Dev. 6.77 10.38
Without varicocele Age < 35 & 
BMI < 25
N 15 13 .1948
Mean 1.46 7.53
Std. Dev. 9.95 14.09
TA B L E  7   Total motility (%)
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hand, it is important to avoid complete ROS clearance because of 
their essential role in sperm maturation and function (de Lamirande 
et al., 1997; Zini, San Gabriel, & Baazeem, 2009). Otherwise, the 
body might go from oxidative stress into a condition characterised by 
an excessive amount of antioxidants, namely reductive stress, which 
is reportedly as dangerous as oxidative stress and is involved in nu-
merous pathologies including cardiomyopathy, cancer, Alzheimer's 
disease or embryogenesis defects (Henkel, Sandhu, & Agarwal, 2019; 
Lloret, Fuchsberger, Giraldo, & Vina, 2016; Rajasekaran et al., 2007).
Even though the association of age and BMI as potential risk fac-
tors for male infertility has not yet been definitively established, we 
investigated the effect of ageing and obesity on the efficacy of an 
antioxidant supplementation therapy for male fertility. To the best 
of our knowledge, this report is the first analysing the effect of anti-
oxidants on sperm parameters with particular emphasis on how such 
therapy could be affected by age and BMI. The results are surprising 
because initially we expected a strong beneficial effect of the sup-
plementation in older and obese patients because of the oxidative 
stress typical of these conditions. In reality, we found exactly the 
opposite and our data appear to show that in patients older than 
35 years and in obese men with a BMI higher than 25, the antioxi-
dant treatment was less effective improving semen quality. In partic-
ular, we observed a statistically significant difference on the effect 
of antioxidants on sperm total motility in favour of those younger 
than 35 and a significant difference on total sperm count, progres-
sive motility and total motility in favour of patients with a BMI less 
than 25. As a result, we consider supplementation more effective in 
younger and normal weight subjects. Perhaps, it might be beneficial 
to increase the antioxidant dosage for obese and older patients in 
order to increase the efficacy and improve sperm quality. Our results 
also call for the inclusion of a diagnostic measure of oxidative stress 
such as oxidation-reduction potential (ORP) in order to establish the 
need of these patients to be supplemented with antioxidants and 
treat male infertility (Agarwal & Wang, 2017). Such diagnostic deter-
mination of the ORP could assist in better defining the dosage and 
duration of supplementation therapy and subject of future study.
Despite the significant positive findings, our trial has some lim-
itations. Even as a double-blind placebo-controlled study with a bal-
anced population and very strict inclusion and exclusion criteria, we 
did not include sperm DNA fragmentation as an important param-
eter to evaluate infertility. Also, an oxidative stress measure such 
as ORP was not included. There also may be other factors besides 
ageing and obesity involved, including lifestyle habits, associated 
disease and fat distribution, and these may require further analysis.
5  | CONCLUSION
In addition to earlier findings regarding improved sperm parameters 
in supplemented patients, these post hoc analyses suggest that an-
tioxidant supplementation seems to be more effective on improving 
sperm parameters in subjects aged less than 35 years old and with 
BMI below 25.
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